



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

REGD. OFFICE & FACTORY : 69/C GIDC INDUSTRIAL ESTATE,
VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA
TEL : 0260-2430027 / 2400639
E-mail: hmr@gtbl.in.net

GTBL: CS: BSE-CORR/2020-21

13th August, 2020

BSE Limited,

P. J. Towers, Dalal Street,
Mumbai-400001

Dear Sir/Madam,

Sub: Outcome of Board Meeting under Reg. 30 of SEBI (LODR) Regulations, 2015

Meeting Commencement Time : 11:00 A.M
Meeting Conclusion Time : 11:45 A.M

The Board of Directors at its meeting held today, considered and approved the following matters:

1. Unaudited Financial Results of the Company for the Quarter ended 30th June, 2020.

A copy of Unaudited Financial Results of the Company for the Quarter ended 30th June, 2020 together with Limited Review Report is enclosed herewith.

2. Confirmed the time, and date of the 39th Annual General Meeting which will be held on Monday, 21st September, 2020 at 12:00 Noon.
3. Closure of Register of Members and Share Transfer Books from Monday, 14th September, 2020 to Monday, 21st September, 2020 for the purpose of 39th Annual General Meeting and payment of dividend for the financial year 2019-20, if approved at the ensuing Annual General Meeting.

This may be taken as compliance under the Listing Regulations.

Kindly take the same on record and acknowledge receipt.

Thanking you,

Yours Faithfully,

For **Gujarat Themis Biosyn Limited**

PK Bodha

Parag Bodha
Company Secretary and Compliance officer



Limited Review report on quarterly unaudited financial results of Gujarat Themis Biosyn Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Gujarat Themis Biosyn Limited

We have reviewed the accompanying statement of unaudited financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended June 30, 2020 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement is the responsibility of the Company's management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Attention is drawn to the fact that the figures for the 3 months ended 31 March 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other accounting practices and policies generally accepted in India, has not disclosed the information



required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GMJ & Co
Chartered Accountants
FRN: 103429W



CA S. Maheshwari
Partner
M. No. 038755
UDIN: 200387 55AAAA DB3869

Place : Mumbai
Date : August 13, 2020



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the quarter ended June 30, 2020

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Year Ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Income from operations	1,566.30	2,635.23	1,170.74	8,512.44
II	Other Income	85.93	28.65	69.44	170.42
III	Total Income (I+II)	1,652.24	2,663.88	1,240.18	8,682.86
IV	Expenditure				
	(a) Cost of raw material consumed	474.48	500.54	8.99	1,544.45
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-Progress and Stock in Trade	(456.18)	(160.84)	-	(410.67)
	(d) Employee benefits expense	167.82	178.12	138.46	643.17
	(e) Finance Cost	23.36	30.19	13.11	92.33
	(f) Depreciation and Amortisation expenses	33.93	39.25	31.16	136.20
	(g) Other Expenses	-	-	-	-
	i) Stores and spares	94.66	120.32	74.18	413.13
	ii) Power	362.07	390.62	446.11	1,730.12
	iii) Fuel	99.66	121.27	108.52	458.81
	iv) Water	19.46	24.30	24.90	96.70
	v) Other expenditure	145.20	138.26	198.19	852.96
	Total Expenses	964.47	1,382.00	1,043.62	5,557.19
V	Profit (Loss) before Exceptional Items and Tax (III-IV)	687.77	1,281.88	196.56	3,125.66
VI	Exceptional items	-	-	-	-
VII	Profit (Loss) before Tax (V-VI)	687.77	1,281.88	196.56	3,125.66
VIII	Tax expenses				
	(a) Current Tax	130.00	202.91	26.50	763.55
	(b) Deferred Tax	0.53	(16.23)	28.80	(5.35)
IX	Net Profit (Loss) after tax (VII-VIII)	557.24	1,095.19	141.26	2,367.46
X	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss				
	(i) remeasurement of defined benefit plans;	0.03	0.13	0.04	0.13
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	(0.01)	(0.03)	(0.01)	(0.03)

GUJARAT THEMIS BIOSYN LIMITED**CIN: L24230GJ1981PLC004878****69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat****Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in**

	b) Items that will be reclassified to Profit or Loss				
	(i) Income Tax relating to items that will be reclassified to Profit or Loss				
XI	Total Comprehensive Income for the period (IX+X)	557.27	1,095.29	141.29	2,367.56
XII	Paid-up equity share capital	726.40	726.40	726.40	726.40
XIII	Other Equity	-			3,493.11
XIV	Earnings Per Share (Basic and Diluted)	3.84	7.54	0.97	16.30

Notes:

- 1 The financial results for the quarter ended June 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 13, 2020.
- 2 Operating segments are reported in manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") of the Company. The CODM, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (CEO) of the Company. The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 The COVID pandemic is unprecedented and has affected the operations as well as results of the Company. The manufacturing facility of the Company which was shut down in the last week of March 2020 due to country wide lockdown, resumed operations in a phased manner from the first week April ,2020 after receiving requisite approvals.

The Company has taken adequate precautions for safety and well - being of the employees while resumption of operations of its plant. The Company has taken into consideration the impact of the known internal and external events arising from COVID - 19 pandemic while preparing the financial information and have considered the possible effects on the carrying amounts of trade receivables and inventories. However, the impact assessment of COVID - 19 is an on - going process, given the uncertainties associated with its nature and duration, hence the same may differ from that estimated as at the date of approval of these financial results.

The Company will continue to closely monitor any material changes to future economic conditions and the consequent impact on its business, If any.

- 5 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

Place: Mumbai**Date : August 13, 2020****For GUJARAT THEMIS BIOSYN LIMITED****DINESH S
PATEL****Dr. DINESH PATEL****Chairman****DIN : 00033273**

Digitally signed by DINESH S PATEL
 DN: c=IN, o=Personal, postalCode=400056,
 st=Maharashtra,
 2.5.4.201a32e148591e86ac1b7b4d9278933e1e075ac7d9a5
 3b3ccadd2a9e278e1f118cb6,
 serialNumber=e4e7ce279ba9f8bce0365c8e25d53e56076
 01b8e0c41e48b0831556a7d21c, cn=DINESH S PATEL
 Date: 2020.08.13 12:08:23 +05'30'